Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

New York State Psychiatric Institute

Status and phase: Completed; Phase 3; Phase 2

Conditions: Opioid-use Disorder

Treatments: Drug: Placebo; Drug: Lorcaserin

Study type: Interventional

Funder types: Other

Identifiers

NCT03169816

7501

Details and patient eligibility

About

This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or placebo (N = 20) with weekly therapy.

Full description

The study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or placebo (N = 20) with weekly therapy. Lorcaserin or placebo 10 mg bid will be started on Day 1 of the study to address acute withdrawal, then maintained over the next 5 weeks, and stopped after the second XR-naltrexone is administered. Patients will be seen twice weekly for monitoring and offered two injections of naltrexone; at the end of oral naltrexone induction (end of week 1) and four weeks later (week 5). The primary outcome measures will be the proportion of patients successfully inducted onto XR-naltrexone.

Enrollment: 60 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 1. Individuals between the ages of 18-60

  2. Meets DSM-5 criteria of current opioid use disorder present for at least six months, supported by a positive urine for opioids

  3. Seeking treatment for opioid use disorder

  4. Capable of giving informed consent and complying with study procedures

  5. Not underweight; defined as BMI≥18.5

Exclusion criteria

1. Lifetime history of DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
2. Current DSM-5 criteria for any other psychiatric disorder that in the investigator's judgment is unstable, would be disrupted by the study medication, or is likely to require pharmacotherapy or psychotherapy during the study period. Concurrent treatment with other psychotropic medication is exclusionary.
3. Individuals who meet DSM-5 criteria for any substance use disorders - severe, other than opioid and nicotine use disorder. Physiological dependence on alcohol or sedative-hypnotics is exclusionary.
4. A recent history of binge-use of alcohol or sedative-hypnotics (using large amounts in a short time to severe intoxication or blackouts).
5. Pregnancy, lactation, or failure to use adequate contraceptive method in female patients who are currently engaging in sexual activity with men.
6. Unstable medical conditions, such as AIDS, cancer, uncontrolled hypertension (blood pressure > 140/90), uncontrolled diabetes, pulmonary hypertension or heart disease.
7. Legally mandated to participate in a substance use disorder treatment program.
8. Current or recent history of significant violent or suicidal behavior, risk for suicide or homicide
9. Currently meets DSM-5 diagnosis for an eating disorder with low body weight (BMI <20)
10. History of accidental opioid overdose in the last three years or any other significant history of overdose following detoxification within past 10 years defined as an episode of opioid-induced unconsciousness, whether or not medical treatment was sought or received.
11. Elevated liver function tests (AST and ALT > 3 times the upper limit of normal) or impaired renal function (GFR<60 ml/min)
12. Known history of allergy, intolerance, or hypersensitivity to lorcaserin, naltrexone or any other study medications
13. Concurrent use of migraine medications containing ergotamine (Cafergot, Ergomar) or dihydroergotamine (Migranal), 5HT2B receptor agonists like cabergoline, or medications metabolized by CYP2D6 (thioridazine, tamoxifen, metoprolol, aripiprazole, codeine)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 2 patient groups, including a placebo group

Lorcaserin

Experimental group

Description:

10 mg capsule taken twice daily of lorcaserin

Treatment:

Drug: Lorcaserin

Placebo

Placebo Comparator group

Description:

a placebo comparator capsule taken twice daily

Treatment:

Drug: Placebo